Symptômes musculaires associés aux statines : quelle prise en charge en 2018 ? [Statin-associated muscle symptoms : Current management in 2018]

Details

Serval ID
serval:BIB_4F41D506D771
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Symptômes musculaires associés aux statines : quelle prise en charge en 2018 ? [Statin-associated muscle symptoms : Current management in 2018]
Journal
Revue medicale suisse
Author(s)
Kosinski C., Tran C., Kuntzer T., Rodondi N., Collet T.H.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
28/02/2018
Peer-reviewed
Oui
Volume
14
Number
596
Pages
462-469
Language
french
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Statins are the first line treatment in hyperlipidemia, either in primary or secondary prevention of cardiovascular diseases. One of the most prescribed drug class worldwide, this drug class is often the focus of highly publicized drug controversies. Various adverse effects have been attributed to statins, in particular statin-associated muscle symptoms (SAMS). This condition varies in severity (from frequent isolated myalgia to rare severe myositis, even rhabdomyolysis) and often leads to treatment termination. Because SAMS are a daily challenge in clinical practice, we review here the recent medical literature on this topic and suggest a management strategy to be shared with the patient as an active partner.
Keywords
Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects, Hyperlipidemias, Muscular Diseases/chemically induced, Myalgia/chemically induced, Myositis/chemically induced, Rhabdomyolysis/chemically induced, Rhabdomyolysis/drug therapy
Pubmed
Create date
03/03/2018 13:03
Last modification date
20/08/2019 14:05
Usage data